Posted by Michael Wonder on 17 Oct 2022
Amryt receives reimbursement approval from the Dutch Ministry of Health for Myalepta (metreleptin)
17 October 2022 - Amryt receives reimbursement approval from the Dutch Ministry of Health for Myalepta (metreleptin).
Amryt announces that the Dutch Ministry of Health has approved Myalepta (metreleptin) for reimbursement in the Netherlands as an adjunct to diet as replacement therapy for the treatment of leptin deficiency in patients with congenital or acquired general lipodystrophy in adults and children two years of age and above.
